Menu
Start Screening

Frontier mental health research: psychedelics & drug studies

Each month our editorial team sifts through hundreds of papers and curates notable findings—for practitioners and informed readers who want to stay current with the evidence. Subscribe to the monthly Research Digest for expert analysis and concise summaries of key papers.

Natural Compound Pharmacology Studies Psilocybin Anxiety or worry

1 paper

Psilocybin for Anxiety or worry

Based on 25 papers

Research so far paints a cautiously hopeful picture about using psilocybin to reduce anxiety. Small clinical trials and reviews show that, when psilocybin is given together with careful therapy and support, some people — especially those facing life‑threatening illness — report less anxiety for weeks or months. However, most studies are small or early stage, and scientists say we need bigger, better trials before we can be sure how well it works, who it helps, and how safe it is long term.

Key findings

  • Controlled trials where psilocybin was given together with psychotherapy have reduced anxiety and depression in patients facing life‑threatening cancer. 15063 15055 15056
  • Reviews of trials for diagnosed anxiety disorders found overall symptom reductions after psychedelic treatments, but only one of the nine trials reviewed used psilocybin specifically and the studies were small. 15068 15056
  • Most research uses psilocybin inside a larger therapy program with hours of preparation and follow‑up, and that therapy seems to matter for both benefits and safety. 15065 15063 15086
  • Laboratory and brain imaging work suggests psilocybin acts on serotonin receptors, can lower activity in a brain network linked to self‑focused worry (the default mode network), and may boost the brain’s ability to form new connections — all possible ways it might affect anxiety. 15132 15050 15135 15091
  • In controlled clinical settings, studies report that psilocybin generally has an acceptable short‑term safety profile, but the drug can cause very strong psychological effects and, rarely, longer‑lasting changes in perception or serious distress. 15135 15055 15080
  • Overall evidence quality is limited: many positive results come from small trials, special groups (like cancer patients), or early‑stage studies, so larger and better controlled trials are still needed. 15056 15078 15087
  • Most published trials included mainly White participants, so we do not know if the findings apply across different racial or cultural groups. 15095
  • A large national survey found people who used psychedelic mushrooms reported higher anxiety and depression scores, but this is an observational finding and cannot show whether mushrooms caused those problems or were used by people already struggling. 15054
  • Some proposed biological markers are unclear: for example, a pooled analysis of many studies found no consistent change in blood BDNF (a protein linked to brain growth) after psychedelic drugs, so the brain‑level explanation is still uncertain. 15129

Inclusion of people of color in psychedelic-assisted psychotherapy: a review of the literature

Timothy I. Michaels, Jennifer Purdon, Alexis Collins, Monnica T. Williams
BMC Psychiatry Summary & key facts 2018 247 citations

The authors reviewed psychedelic-assisted psychotherapy studies published from 1993 to 2017 to see how many people of color took part. They found 18 studies with about 280 people. About 82% of participants were non-Hispanic White, while only small percentages were African American, Latino, Asian, indigenous, or mixed race. Because so…

Natural Compound Pharmacology Studies Neurotransmitter Receptor Influence on Behavior Psychedelics and Drug Studies Ayahuasca LSD
Summaries and links are for general information and education only. They are not a substitute for reading the original publication or for professional medical, legal, or other advice. Always refer to the linked source for the full study.